PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33853291-11	2021	After PMX-DHP, the mean P/F ratio improved (86 [range, 63-106] vs. 145 [86-260], P=0.030) and interleukin-6 and c-reactive protein decreased (79 [35-640] vs. 10 [5-25], P=0.018 and 14 [4-21] vs. 5 [2-6], P=0.019, respectively).	pmx-dhp	6-13	C-reactive protein	Homo sapiens	112-130	
35566611-8	2022	Also, white blood cells (WBCs) and C-reactive protein (CRP) were decreased after PMX-DHP treatment.	pmx-dhp	81-88	C-reactive protein	Homo sapiens	35-53	
35566611-8	2022	Also, white blood cells (WBCs) and C-reactive protein (CRP) were decreased after PMX-DHP treatment.	pmx-dhp	81-88	C-reactive protein	Homo sapiens	55-58	
33423442-9	2020	PMX-DHP subsequently improved oxygenation (PaO2/FiO2 ratio) and decreased the levels of inflammatory markers (interleukin-6, C-reactive protein, and white blood cells).	pmx-dhp	0-7	C-reactive protein	Homo sapiens	125-143	
19994591-8	2009	In 4 patients who survived for 60 days or longer, serum levels of LDH, CRP, and SP-D were significantly decreased after PMX-DHP, whereas KL-6 level was unchanged.	pmx-dhp	120-127	C-reactive protein	Homo sapiens	71-74	
19994591-10	2009	These data suggest that serum levels of LDH, CRP, and SP-D might be predictive of successful PMX-DHP treatment in cases of IP-AE.	pmx-dhp	93-100	C-reactive protein	Homo sapiens	45-48